公开(公告)号：US11952400B2

公开(公告)日：2024-04-09

申请号：US17232952

申请日：2021-04-16

申请人： TECON BIOPHARMACEUTICAL CO., LTD.

发明人： Sun He ,  Yiping Pan ,  Guoqing Zhang ,  Pengxian Yan ,  Na Xi ,  Miaomiao Guo ,  Shengdong Xiao ,  Tianzeng Li ,  Rui Han ,  Yumeng Wang ,  Jiubin Du ,  Pei Zheng ,  Jian Cao

IPC分类号： C07K14/005 ,  A61K39/108 ,  A61K39/15 ,  C07K14/245 ,  C12N7/00 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K39/0258 ,  A61K39/15 ,  C07K14/245 ,  C12N7/00 ,  A61K2039/5258 ,  A61K2039/552 ,  A61K2039/70 ,  C07K2319/40 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12334 ,  C12N2720/12352 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2770/20052

摘要： Provided are a bovine rotavirus fusion protein and calf diarrhea multivalent vaccine. The bovine rotavirus fusion protein contains a VP6 fragment, wherein the VP6 fragment contains an amino acid sequence as represented by SEQ ID NO. 4, and at least one loop region of the following (a)˜(c) is substituted with an antigenic epitope derived from bovine coronavirus and/or an antigenic epitope derived from E. coli: (a) amino acid residues of sites 168-177; with an amino acid sequence as represented by SEQ ID NO. 1; (b) amino acid residues of sites 194-205; with an amino acid sequence as represented by SEQ ID NO. 2; and (a) amino acid residues of sites 296-316, with an amino acid sequence as represented by SEQ ID NO. 3, The bovine rotavirus fusion protein contains a plurality of antigenic epitopes, and can enable a host to generate a plurality of antibodies after immunizing the host.

公开(公告)号：US09862933B2

公开(公告)日：2018-01-09

申请号：US14429586

申请日：2013-06-24

申请人： Xiamen University ,  Xiamen Innovax Biotech Co., Ltd.

发明人： Shengxiang Ge ,  Tingdong Li ,  Qingshun Guo ,  Feihai Xu ,  Jun Zhang ,  Ningshao Xia

IPC分类号： C12N7/04 ,  C12N7/00 ,  A61K38/16 ,  A61K39/00

CPC分类号： C12N7/00 ,  A61K38/162 ,  A61K39/00 ,  C12N7/04 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12333 ,  C12N2720/12334 ,  C12N2720/12352

摘要： The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.

公开(公告)号：US20160185826A1

公开(公告)日：2016-06-30

申请号：US15015249

申请日：2016-02-04

申请人： Medigen Biotechnology Corp.

发明人： Young-Sun LIN ,  Jinyi CHENG ,  Ya-Lin CHIANG ,  Ming-Cheng CHEN ,  Kuei-Tai A. LAI ,  Chih Ya YANG

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/29 ,  A61K39/125 ,  A61K39/15 ,  C12N7/00 ,  A61K39/145

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/40 ,  C12N7/00 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12334 ,  C12N2720/12371 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10171 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/16022 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/16071 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/28171 ,  C12N2770/32322 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32371 ,  C12N2770/32422 ,  C12N2770/32423 ,  C12N2770/32434 ,  C12N2770/32471 ,  Y02A50/467

摘要： The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

摘要翻译： 本发明涉及包含这种二聚融合蛋白的二聚融合蛋白和病毒样颗粒。 这些二聚融合蛋白包含携带在两个病毒结构蛋白或其片段之间的抗原或抗原性片段，其具有或不具有接头，相对于传统的单体平台，使抗原或抗原片段和病毒结构蛋白之间的空间位阻最小化 或其片段。 这种新颖的设计提供了多价疫苗和增强的免疫原性。 本发明还涉及编码这种二聚融合蛋白的核酸和包含这种核酸的宿主细胞。 本发明还涉及包含本发明的二聚融合蛋白和/或病毒样颗粒的药物组合物，以及使用这种组合物的预防或治疗方法。

公开(公告)号：US20110171316A1

公开(公告)日：2011-07-14

申请号：US12995024

申请日：2009-05-29

申请人： Baoming Jiang

发明人： Baoming Jiang

IPC分类号： A61K39/15 ,  C07K14/14 ,  A61K9/14 ,  C12P21/00 ,  A61P37/04 ,  A61P31/14 ,  C12Q1/02

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  C12N2710/14143 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12334

摘要： Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions.

摘要翻译： C组轮状病毒是与A组RV不同的儿童和成人的急性胃肠炎的原因。 然而，人类C型轮状病毒不能在培养物中生长，导致缺乏用于检测和治疗GrpC RV疾病的工具。 因此，GpC RV疾病的负担尚未明确。 根据本发明的实施方案提供分离的重组人轮状病毒组C病毒样颗粒以及其生产和用于特别是检测Grp C RV感染，诊断测定和免疫原性组合物的方法。

公开(公告)号：US20180016561A1

公开(公告)日：2018-01-18

申请号：US15545362

申请日：2016-01-21

申请人： MEDICAGO, INC. ,  MITSUBISHI TANABE PHARMA CORPORATION

发明人： Pierre-Olivier LAVOIE ,  Marc-Andre D'AOUST

IPC分类号： C12N7/04 ,  C12N15/82 ,  A61K39/12 ,  C12N15/86 ,  C12N7/02 ,  A61K39/00

CPC分类号： C12N7/04 ,  A61K39/12 ,  A61K2039/5258 ,  C12N7/02 ,  C12N15/8257 ,  C12N15/86 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12334 ,  C12N2720/12351

摘要： A method of producing a rotavirus-like particle (RLP) in a plant is provided. The method comprises expressing within a host or host cell for example a plant, portion of a plant or plant cell one or more nucleic acid comprising one or more regulatory region operatively linked to a first, second and third nucleotide sequence, the regulatory region active in the host or host cell. The first nucleotide sequence encoding a first rotavirus protein, the second nucleotide sequence encoding a second rotavirus protein and the third nucleotide sequence encoding a third rotavirus protein. The first, second and third encode rotavirus protein NSP4 and VP2 or VP6 and VP4 or VP7. The host or host cell is incubated under conditions that permit the expression of the nucleic acids, so that NSP4 and either VP2 of VP6 and VP4 or VP7 are expressed, thereby producing the RLP. Hosts comprising the RLP, compositions comprising the RLP and method for using the composition are also provided.

公开(公告)号：US20160038586A1

公开(公告)日：2016-02-11

申请号：US14819684

申请日：2015-08-06

申请人： Medigen Biotechnology Corp.

发明人： Young-Sun Lin ,  Jinyi Cheng ,  Ya-Lin Chiang ,  Ming-Cheng Chen ,  Kuei-Tai A. Lai ,  Chih Ya Yang

IPC分类号： A61K39/29 ,  C12N7/00 ,  C07K14/005

CPC分类号： A61K39/292 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55572 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K14/005 ,  C07K2319/40 ,  C12N7/00 ,  C12N2720/12323 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10151 ,  C12N2730/10171 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/16042 ,  C12N2770/16051 ,  C12N2770/16071 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32371 ,  Y02A50/467

摘要： The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

摘要翻译： 本发明涉及包含这种二聚融合蛋白的二聚融合蛋白和病毒样颗粒。 这些二聚融合蛋白包含携带在两个病毒结构蛋白或其片段之间的抗原或抗原性片段，其具有或不具有接头，相对于传统的单体平台，使抗原或抗原片段和病毒结构蛋白之间的空间位阻最小化 或其片段。 这种新颖的设计提供了多价疫苗和增强的免疫原性。 本发明还涉及编码这种二聚融合蛋白的核酸和包含这种核酸的宿主细胞。 本发明还涉及包含本发明的二聚融合蛋白和/或病毒样颗粒的药物组合物，以及使用这种组合物的预防或治疗方法。

公开(公告)号：US20060165723A1

公开(公告)日：2006-07-27

申请号：US11217338

申请日：2005-09-02

申请人： Luis Enjuanes Sanches ,  Esteban Domingo-Solans ,  Juan Duran ,  Francisco Ortego ,  Juan Ceriani

发明人： Luis Enjuanes Sanches ,  Esteban Domingo-Solans ,  Juan Duran ,  Francisco Ortego ,  Juan Ceriani

IPC分类号： C07K14/005 ,  C12Q1/70 ,  C07H21/04 ,  C12P21/06 ,  A61K39/15 ,  C12N15/86

CPC分类号： C07K14/005 ,  A61K2039/5256 ,  A61K2039/5258 ,  C12N15/86 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2770/20022 ,  C12N2770/20043 ,  C12N2770/32122 ,  C12N2770/32123 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2840/20 ,  C12N2840/203

摘要： The present invention relates to nucleic acids comprising: (a) sequences of a replication competent transmissible gastroenteritis virus (TGEV), which sequences encode a TGEV replicase under the control of expression regulatory sequences so that expression of the replicase in a cell containing the nucleic acid will initiate replication of the nucleic acid and thus increase the number of nucleic acids in the cell; and (b) sequences encoding one or more proteins of a different virus wherein the one or more proteins are capable of associating into a virus-like particle (VLP) that does not contain any infectious nucleic acid. The present invention further relates to vectors, virus particles and host cells comprising these nucleic acids as well as their use for the preparation of vaccines, specifically for the preparation of vaccines.

摘要翻译： 本发明涉及核酸，其包含：（a）复制型传染性胃肠炎病毒（TGEV）的序列，其在表达调控序列的控制下编码TGEV复制酶，使得复制酶在含有核酸的细胞中的表达 将启动核酸的复制，从而增加细胞中核酸的数量; 和（b）编码不同病毒的一种或多种蛋白质的序列，其中所述一种或多种蛋白质能够结合成不含任何感染性核酸的病毒样颗粒（VLP）。 本发明还涉及包含这些核酸的载体，病毒颗粒和宿主细胞以及其用于疫苗制备，特别是疫苗的制备的用途。

公开(公告)号：US20160188790A1

公开(公告)日：2016-06-30

申请号：US14900829

申请日：2014-07-08

申请人： NOVARTIS AG ,  CHILDREN'S MEDICAL CENTER CORPORATION ,  BRANDEIS UNIVERSITY

发明人： Philip R. Dormitzer ,  Nikolaus Grigorieff ,  Stephen Harrison ,  Junhua Pan ,  Ethan Settembre

IPC分类号： G06F19/16 ,  G06F19/12 ,  C12Q1/02 ,  C07K14/005 ,  C12N7/00

CPC分类号： G06F19/16 ,  C07K14/005 ,  C07K14/14 ,  C07K2319/42 ,  C07K2319/50 ,  C07K2319/70 ,  C07K2319/73 ,  C07K2319/735 ,  C12N7/00 ,  C12N2720/12321 ,  C12N2720/12323 ,  C12N2720/12351 ,  C12Q1/02 ,  G06F19/12

摘要： The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunising a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.

摘要翻译： 本发明涉及轮状病毒颗粒在单独或与另一种分子复合物中显示异源蛋白质的用途。 本发明还涉及使用这些修饰轮状病毒颗粒使用低温电子显微镜（cryo-EM）快速确定异源蛋白质或复合物的结构的方法。 本发明还涉及免疫患者的方法，其中所述方法包括向患者施用本发明的修饰轮状病毒颗粒。

公开(公告)号：US09169296B2

公开(公告)日：2015-10-27

申请号：US12995024

申请日：2009-05-29

申请人： Baoming Jiang

发明人： Baoming Jiang

IPC分类号： A61K39/12 ,  C12N7/00 ,  C12N7/02 ,  C07K14/005 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  C12N2710/14143 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12334

摘要： Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions.

摘要翻译： C组轮状病毒是与A组RV不同的儿童和成人的急性胃肠炎的原因。 然而，人类C型轮状病毒不能在培养物中生长，导致缺乏用于检测和治疗GrpC RV疾病的工具。 因此，GpC RV疾病的负担尚未明确。 根据本发明的实施方案提供分离的重组人轮状病毒组C病毒样颗粒以及其生产和用于特别是检测Grp C RV感染，诊断测定和免疫原性组合物的方法。

公开(公告)号：US20150252334A1

公开(公告)日：2015-09-10

申请号：US14429586

申请日：2013-06-24

申请人： XIAMEN UNIVERSITY ,  XIAMEN INNOVAX BIOTECH CO., LTD.

发明人： Shengxiang Ge ,  Tingdong Li ,  Qingshun Guo ,  Feihai Xu ,  Jun Zhang ,  Ningshao Xia

IPC分类号： C12N7/00

CPC分类号： C12N7/00 ,  A61K38/162 ,  A61K39/00 ,  C12N7/04 ,  C12N2720/12322 ,  C12N2720/12323 ,  C12N2720/12333 ,  C12N2720/12334 ,  C12N2720/12352

摘要： The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.

摘要翻译： 本发明涉及一种体外制备轮状病毒双层病毒样颗粒的方法。 该方法包括以下步骤：从裂解上清液中纯化轮状病毒VP6蛋白，以及体外组装由VP2蛋白和VP6蛋白组成的双层病毒样颗粒，其中蛋白质和病毒样颗粒可用于预防或 减少轮状病毒感染引起的临床症状。